Investor Relations Home
Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.
|Recent Press Releases||More >>|
|Date||Title|| || |
|12/05/13||Omeros to Present at Oppenheimer 24th Annual Healthcare Conference|
|SEATTLE, Dec. 5, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York City next week. The presentation is scheduled for Wednesday, December 11, 201... || |
|11/20/13||Omeros Announces FDA Acceptance of Omidria™ as Proprietary Name for OMS302|
|-- European Medicines Agency Review of Proposed Names to be Completed Soon --
SEATTLE, Nov. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Omidria™ for OMS302, the Company's proprietary product in development for use in intraoperative lens replacement (ILR) surgery. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of th... || |
|11/19/13||Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting|
|-- In These Clinical Trials, OMS302 Reduced Incidence of Miosis --
SEATTLE, Nov. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported analyses of Phase 3 clinical data showing the impact of OMS302 on reducing the incidence of miosis (pupil constriction) during intraocular lens replacement (ILR). OMS302 is the company's proprietary Pharmacosurgery® product being developed for all ILR, including cataract surgery and refractive lens exchange.
The analyses were presented ... || |
|11/12/13||Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting|
|-- OMS302 also to be Featured in "Cutting Edge" Symposium --
SEATTLE, Nov. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present data from its Phase 3 clinical program for OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which will take place from November 16 through November 19 in New Orleans, Louisiana. The presentation, "Two Phase 3 Trials of OMS302 in Irrigation Solution for Maintenance of Mydriasis in Intraocular Lens Replace... || |
|12/11/13 1:35 p.m. ET|
Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.